Skip to main content
HomeAnnual Spring Conference 2024



6:30 AM          Registration, Continental Breakfast and Exhibit Hall


7:00 AM          Epidemiologic Trends in Adult Invasive Pneumococcal Disease and          Unmet Needs (no CE)

                       Tana Kaefer, PharmD

                       Merck Product Theater


8:00 AM          Welcome and Opening Remarks

                       MPhA President


8:10 AM          The Overdose Response Strategy


9:15 AM          Motion to Proceed! Moving Pharmacy Forward.


10:15 AM        Break – Exhibit Hall Opens


10:30 AM        Regulatory Updates April 2024


11:35 AM        Current and Future Therapies for the Management of Diabesity (Diabetes and Obesity)



12:35 PM        Lunch/ Exhibit Hall Open

                        Management of Hypoglycemia (no CE)

                        Jennifer D. Goldman, RPh, PharmD, CDCES. BC-ADM, FCCP

                        Xeris Pharmaceuticals Product Theater       


1:40 PM          Pipeline Preview 2024



2:45 PM          Immunization Update: One Patient at a Time


3:50 PM          Advancements in UTI Treatment: Exploring the Latest Updates and Strategies for Improved Patient Outcomes





Learning Objectives and Speaker Credentials

This program is NOT accredited for pharmacy technicians.



The Overdose Response Strategy

Amanda Consigli, Public Health Analysis,

Mike Sampson Drug Intelligence Officer.

New England High Intensity Drug Trafficking Area (HIDTA)

  • Learners will be able to identify three strategies pharmacists can utilize to reduce overdose risk among their patient population.
  • Learners will be able to describe the threat of counterfeit prescription drugs in their communities.
  • Learners will be able to report what substances are in the current drug supply in Massachusetts and list the emerging threats.

UAN 0576-9999-24-007-L01-P; 1 contact hour – knowledge-based

Motion to Proceed: Moving Pharmacy Forward

Senator Cindy Freidman

  • Explain the steps in the legislative process.
  • Identify the key elements of the Pharmaceutical Access, Costs and Transparency (PACT) Act and next steps.
  • Recognize the impact that advocacy by pharmacists can have on the legislative process and how to efficiently do so.

UAN 0576-9999-24-013-L03-P; 1 contact hour – knowledge-based


Regulatory Update April 2024

Michelle Chan, RPh

Julienne Tran, RPh

Massachusetts Board of Pharmacy

  • Identify the differences between legislation and regulations.
  • Describe the process to implement new and revised regulations.
  • Summarize new advisories, policies, and circular letters.

UAN 0576-9999-24-010-L03-P; 1 contact hour – knowledge-based


Current and Future Therapies for the Management of Diabesity (Diabetes and Obesity)

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP

Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA

Clinical Pharmacist

Director of Cardiometabolic Services

Well Life Medical, Peabody, MA

  • Describe the American Diabetes Association (ADA) Standards of Care in Diabetes 2024 recommendations for achieving and maintaining glycemic and weight loss goals
  • Explain the mechanism of action of current agents preferred by the ADA for the management of diabetes and obesity
  • Summarize the future therapies and novel mechanisms being studied for the treatment of diabetes and obesity
  • Utilizing patient cases, choose appropriate, evidence-based drug therapy and proper patient counseling

UAN 0576-9999-24-008-L01-P; 1 contact hour – knowledge-based


Pipeline Preview 2024

Maria M. Lowe, PharmD, BCPS

Director of Pharmaceutical Intelligence Institute for Clinical and Economic Review

Boston, MA

  • Describe recent trends in the FDA approval process
  • Identify agents at late stages of development across select therapeutic areas
  • List the first-time generics expected to hit the market within the next two years

UAN 0576-9999-24-009-L01-P; 1 contact hour – knowledge-based


Immunization Update: One Patient at a Time

Courtney Doyle Campbell, PharmD

Clinical Professor of Ambulatory Care

Western New England University; Springfield, MA

  • Describe recent ACIP recommendations.
  • Review common vaccine errors.
  • Discuss the relationship between social determinants of health and vaccine uptake.

UAN 0576-9999-24-012-L06-P; 1 contact hour – knowledge-based


Advancements in UTI Treatment: Exploring the Latest Updates and Strategies for Improved Patient Outcomes

Christina Johnson, PharmD, BCPS

Clinical Pharmacist

Lowell General Hospital, Lowell, MA

  • Describe potential risks in over-prescribing for urinary tract infections (UTIs)
  • Summarize current guidelines and future changes for the managment of patients with UTI
  • Discuss different approaches to decrease antibiotic prescribing in patients with UTI and asymptomatic bacteriuria
  • Evaluate supportive evidence for decreased duration of antibiotic therapy in patients with UTI and uncomplicated bacteremia associated with UTI
  • Apply changes to practice by discussing opportunities to incorporate stewardship into practice

UAN 0576-9999-24-011-L01-P; 1 contact hour – knowledge-based

Statement of Disclosure

In accordance with the Standards for Continuing Pharmacy Education of the Accreditation Council for Pharmacy Education, Western New England University College of Pharmacy and Health Sciences will disclose any interest or affiliation a speaker might have with a supporting commercial organization. Such disclosure will be made available on the day of the program.


Acknowledgement of financial support will be made on the day of the program.


Accreditation Statement



Western New England University College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.




Registration Information:


Fees: The cost of attendance is $149 for MPhA members and $184.99 non-members; bundle (meeting registration and membership) $259.99.  


Advanced registration is required.



Deadline for Registration is April 11, 2024.


Requirements for Credit:

  • Upon completion of the program, attendees will earn 7 contact hours of ACPE accredited Continuing Pharmacy Education.
  • Participants must register the event on WNEU CE platform and complete the activity learning evaluation form by inserting an activity specific code number. The link to the CE platform is Instructions for accessing this website will also be given to participants on the day of the program.

  • Participants must have an NABP ID number to document credit on the CPE Monitor System of the National Association of Boards of Pharmacy.
  • Participants have 30 days to complete assessment of learning/evaluations. After 30 days from April 11, 2024, no credit will be available for this program.

  • Credits will be directly transferred to the National Association of Boards of Pharmacy CPE Monitor System. No Statements of Credit will be issued.


For additional information and questions, please contact Dr. Shusen Sun, Director of Continuing Education, at  or 413-796-2424.

ALL your CE needs in one day!! 7 hours total of LIVE CE, 2 hours of LAW and 1 hour of immunization.

Exhibits, product theaters and networking with colleagues.


Non Members: 184.99

Bundle ( Meeting registration and membership) 259.99


Western New England University (WNE) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants of the 2024 MPhA Spring Conference will receive 7 contact hours (0.7 CEU), including two hours of pharmacy law.

Requirements for Credit

In order to receive credit, the participant must be present the entirety of each presentation and complete the post-tests, and evaluation form for each session. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

Western New England University (WNE) adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of WNE that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.